Ready to leave?
Oops ! Condition name you have entered is invalid.
You are now leaving Aposbook.com and going to an external site managed by another organization.
Please confirm your email address and try to login again.
This account has been deleted. do you want to restore it?
A verification link will be sent to within the next 2 minutes. Please click it to validate your e mail.
*If you didn't get the link, please check your spam folder
You are now a registered user.
Once you log in, you can use our search tool to find all the natural solutions for any health condition. Plus, you can discuss, ask questions, and share your point of view about various topics.
We highly encourage you to write reviews and testimonials about any natural solution you have tried. Regardless of whether the solution was effective or not, we urge you to remain authentic and objective. Our ultimate aim is to help each other learn the truth about each solution. You can also add content you may find interesting in the library center section.
Together, we can contribute to our community’s knowledge.
Sincerely,
The Aposbook Team
A validation link will be sent to you by email. Please confirm your address to log in
*If you didn't get the link, please check your spam folder
Please log in to use this feature
Your account has been suspended because you have violated our code of conduct. If you think this was a mistake, you can contact us by email at: support@aposbook.com "Contact us" form.
Success! Thank you for your feedback. Your contribution can make a difference. Together we can help each other.
1999 March
K Hara, Y Akiyama, T Tomiuga, M Kobayashi, H Kawashima
Abstract
Vitamin K2(K2), a therapeutic agent osteoporosis, is prohibited for patients with thrombosis who are receiving warfarin (WF). However, because some aged patients with thrombosis have osteoporosis, some patients treated with WF may be administered K2 concomitantly.
We investigated here the interaction between K2 and WF on thrombosis in a rat aorta loop model. Administration of WF at 0.58, 0.82 and 1.16 mg/l in drinking water for 7 days decreased the thrombotic rate and increased the death rate, dose-dependently. Therefore in the following study, 0.80 mg/l of WF was used.
After 2 days of WF-treatment, 1.5, 14 and 145 mg/kg of K2 was administered for 5 days. The blood coagulation time was markedly prolonged by WF treatment for 7 days and this effect was completely inhibited by all doses of K2. WF treatment significantly decreased the cumulative thrombotic rate for 5 days.
Administration of 1.5 and 14 mg/kg of K2 did not influence the WF effect on thrombosis. The thrombotic rate in the 145 mg/kg K2 group was lower than that in the WF-control group, but similar to that in the WF-untreated group.
These findings suggest that high dose of K2 reduces the effect of WF on thrombosis but does not enhance the occurrence of thrombosis more than that without WF treatment.
Taking Vitamin D and Calcium Without K2 Can Increase Heart Attack Risk
Vitamin K and Warfarin Correlation
VITAMIN K2 BENEFITS | MK7 Dosage Recommendations 2020